ANDA 207551, held by Amneal Pharmaceuticals. Dexmedetomidine Hydrochloride.
As of Nov 22, 2026, ANDA 207551 (Dexmedetomidine Hydrochloride), held by Amneal Pharmaceuticals, was first approved by FDA on May 20, 2020, with 0 approved supplements and 0 published complete response letters.
Dexmedetomidine hydrochloride is a alpha 2 -adrenergic receptor agonist indicated for: Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer dexmedetomidine hydrochloride in 0.9% sodium chloride injection by continuous infusion not to exceed 24 hours. Sedation of non-intubated adult patients prior to and/or during surgical and other procedures. 1.1 Intensive Care Unit Sedation Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Dexmedetomidine hydrochloride in 0.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 20, 2020 | Original application | Approved | None posted |
| Dexmedetomidine HydrochlorideEQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) · injectable;injection | Dexmedetomidine Hydrochloride | Rx |
| Dexmedetomidine HydrochlorideEQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) · injectable;injection | Dexmedetomidine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters